http://www.gosreports.com
Eosinophilic Esophagitis – Pipeline Review, H2 2021 by Gosreports
Eosinophilic esophagitis is disease characterized by the presence of a large number of a special type of white blood cell, the eosinophil that can cause inflammation in the esophagus. Symptoms include poor weight gain, abdominal pain, nausea, and vomiting, coughing, heartburn and chest pain. Risk factors include weakened immune system, chemotherapy, aspirin and anti-inflammatory medications, chronic vomiting, obesity and alcohol and cigarette use. Treatment includes antiviral, antifungal and pain relievers.
Report Highlights
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Eosinophilic Esophagitis – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Eosinophilic Esophagitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Full Report:
http://www.gosreports.com/global-toilet-rim-blocks-market-research-report-2016/
The Eosinophilic Esophagitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Eosinophilic Esophagitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 5, 2 and 3 respectively for Eosinophilic Esophagitis.
Eosinophilic Esophagitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Table of contents:
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Eosinophilic Esophagitis Overview 7
Therapeutics Development 8
Pipeline Products for Eosinophilic Esophagitis – Overview 8
Eosinophilic Esophagitis – Therapeutics under Development by Companies 9
Eosinophilic Esophagitis – Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Eosinophilic Esophagitis – Products under Development by Companies 13
Eosinophilic Esophagitis – Companies Involved in Therapeutics Development 14
Adare Pharmaceuticals, Inc. 14
Calypso Biotech SA 15
Celgene Corporation 16
DBV Technologies S.A. 17
Dr. Falk Pharma GmbH 18
Novartis AG 19
Panmira Pharmaceuticals, LLC. 20
Quorum Innovations LLC 21
Regeneron Pharmaceuticals Inc 22
Shire Plc 23
Eosinophilic Esophagitis – Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
Allergen for Milk Allergy – Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
AM-211 – Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
AM-461 – Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
budesonide – Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
budesonide – Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
CALY-002 – Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
dectrekumab – Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
dupilumab – Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
fluticasone propionate – Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
fluticasone propionate – Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Qi-201 – Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
RPC-4046 – Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Eosinophilic Esophagitis – Dormant Projects 58
Eosinophilic Esophagitis – Product Development Milestones 59
Featured News & Press Releases 59
Sep 21, 2016: DBV Technologies Receives FDA Fast Track Designation for Viaskin Milk for the Treatment of Cows Milk Protein Allergy 59
Jun 13, 2016: Shire Receives FDA Breakthrough Therapy Designation for Investigational Product SHP621 for Rare Gastrointestinal Conditions 59
Nov 12, 2015: DBV Technologies Announces Enrollment of First Patient in Phase IIA Study in Pediatric Eosinophilic Esophagitis 60
Jul 08, 2015: IND Acceptance from FDA for a proof-of-concept trial using Viaskin Milk in Milk-Induced Eosinophilic Esophagitis in Children 61
Oct 03, 2014: Receptos Announces First Patient Treated With Anti-Interleukin-13 Antibody in Phase 2 Trial for Eosinophilic Esophagitis 61
……………………
More Information:
http://www.gosreports.com/global-thermoelectric-energy-harvesting-devicess-market-research-report-2016/

Contacts Us
Joanna | Executive - International Business and partner Relations
E-mail: [email protected] 
Tel: 001-510-400-8520
Web: www.gosreports.com